Want to see GB:EAH full AI Analyst Report?
EAH Stock Chart & Stats
101.00 p
-5.00 p(-4.95%)
At close: 4:00 PM EDT
101.00 p
-5.00 p(-4.95%)
Day’s Range― - ―
52-Week Range72.00 p - 116.90 p
Previous CloseN/A
Volume655.63K
Average Volume (3M)75.04K
Market Cap
£65.73M
Enterprise Value52.96 p
Total Cash (Recent Filing)£25.43M
Total Debt (Recent Filing)£4.93M
Price to Earnings (P/E)31.0
Beta0.69
Next Earnings
Nov 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.03
Shares Outstanding67,759,674
10 Day Avg. Volume57,390
30 Day Avg. Volume75,042
Financial Highlights & Ratios
PEG Ratio0.95
Price to Book (P/B)0.74
Price to Sales (P/S)0.74
P/FCF Ratio8.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.03
Revenue Forecast (FY)£88.21M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetA very low debt-to-equity position (debt ~£4.9m vs equity ~£87.1m) provides durable financial flexibility. This conservative balance sheet supports funding regulatory approvals, commercial expansion, and absorbing demand shocks without relying on costly external financing over the medium term.
Positive Free Cash Flow GenerationSolid operating and free cash flow in FY2026 gives the company recurring internal funding to support product registrations, working capital and selective reinvestment. Reliable FCF underpins long-term operational resilience and optionality for R&D or strategic deals.
Diversified Revenue ModelA dual business model—own branded pharmaceuticals plus distribution of third-party products—reduces single-product dependency and smooths sales cycles. Built distribution networks and local registrations create durable routes to market and recurring transactional revenue.
Bears Say
Volatile Cash Flows HistoricallyHistorical swings in operating and free cash flow, including negative results in FY2022, indicate inconsistent cash conversion. This variability undermines confidence in funding timing for regulatory spend and commercial investment and raises execution risk over the medium term.
Earnings Well Below Prior PeakAlthough FY2026 showed a rebound, current net income (~£2.2m) remains far below the FY2021 high. This persistent gap suggests structural pressures on margins or scale, implying the business has yet to restore prior profitability sustainably.
Modest Returns On EquityLow ROE indicates the sizeable equity base is not translating into strong profit generation. Without improved margin execution or more efficient capital deployment, shareholder returns may remain muted and the company could struggle to justify its capital intensity.
Eco Animal Health News
EAH FAQ
What was Eco Animal Health Group PLC’s price range in the past 12 months?
Eco Animal Health Group PLC lowest share price was 72.00 p and its highest was 116.90 p in the past 12 months.
What is Eco Animal Health Group PLC’s market cap?
Eco Animal Health Group PLC’s market cap is £65.73M.
When is Eco Animal Health Group PLC’s upcoming earnings report date?
Eco Animal Health Group PLC’s upcoming earnings report date is Nov 19, 2026 which is in 109 days.
How were Eco Animal Health Group PLC’s earnings last quarter?
Eco Animal Health Group PLC released its earnings results on Jul 15, 2026. The company reported 0.038 p earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Eco Animal Health Group PLC overvalued?
According to Wall Street analysts Eco Animal Health Group PLC’s price is currently Overvalued.
Does Eco Animal Health Group PLC pay dividends?
Eco Animal Health Group PLC pays a Notavailable dividend of 1 p which represents an annual dividend yield of N/A. See more information on Eco Animal Health Group PLC dividends here
What is Eco Animal Health Group PLC’s EPS estimate?
Eco Animal Health Group PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Eco Animal Health Group PLC have?
Eco Animal Health Group PLC has 67,759,674 shares outstanding.
What happened to Eco Animal Health Group PLC’s price movement after its last earnings report?
Eco Animal Health Group PLC reported an EPS of 0.038 p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.907%.
Which hedge fund is a major shareholder of Eco Animal Health Group PLC?
Currently, no hedge funds are holding shares in GB:EAH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Eco Animal Health Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
45.77%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-1.70%
Trailing 12-Months
Company Description
Eco Animal Health Group PLC
ECO Animal Health Group plc, established in 1972 and based in New Malden, United Kingdom, focuses on the worldwide research, regulatory approval, and distribution of veterinary pharmaceutical solutions. The company's offerings include Aivlosin, a macrolide antibiotic specifically formulated to address digestive and respiratory illnesses in pigs and poultry. Additionally, its product range encompasses various generic drugs like Ecomectin, Ecoheart, Ecotraz, and Ecomintic. These endectocides and other antiparasitics are designed to manage and prevent parasitic infestations such as worms, ticks, and lice across a diverse array of animals, including cattle, sheep, pigs, horses, and dogs. ECO Animal Health Group also provides Chlortetracycline and Oxytetracycline for treating bacterial infections in swine, fowl, and bovine animals.